Income statement
USD
Annual
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 263K | 1M | 1M | 2M | 4M |
| Gross Profit | 263K | 1M | 1M | 2M | 4M |
| Operating Income | -3M | -2M | -5M | -6M | -6M |
| EBITDA | -2M | -3M | -4M | -10M | -3M |
| Net Income | -2M | -3M | -4M | -10M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.17
-7.31% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cytocom, Inc. (CBLI) is a Healthcare stock with a market cap of $226.39M. The stock last traded around $3.17. Baseline metrics include revenue growth of -76.4%, EPS growth of +17.4%, a dividend yield of 0.0%. What stands out right now is revenue -76.4%, EPS +17.4%, free cash flow +11.0% with operating margin -983.7% and ROIC -55.6%. Valuation already assumes a fairly strong business story at price/sales 861.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CBLI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CBLI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CBLI Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CBLI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.5M
+80.6% YoY
FY Net Income
-$2.7M
+72.6% YoY
Free Cash Flow
-$5.0M
+23.7% YoY
Revenue Growth
-76.4%
EPS Growth
+17.4%
Gross Margin
100.0%
Net Margin
-912.2%
Income statement
USD
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 263K | 1M | 1M | 2M | 4M |
| Gross Profit | 263K | 1M | 1M | 2M | 4M |
| Operating Income | -3M | -2M | -5M | -6M | -6M |
| EBITDA | -2M | -3M | -4M | -10M | -3M |
| Net Income | -2M | -3M | -4M | -10M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 1M | 4M | 4M | 7M |
| Total Assets | 2M | 2M | 5M | 10M | 16M |
| Total Liabilities | 305K | 1M | 920K | 2M | 3M |
| Shareholder Equity | 2M | 984K | 4M | 7M | 13M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -2M | -1M | -4M | -4M | -7M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+23.8% YoY
Capital Expenditures
10K
-132.7% YoY
Free Cash Flow
5M
+23.7% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-983.7%
Net Margin
-912.2%
ROE
-160.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.